DEXBROMPHENIRAMINE

US Approved OTC

First approved in 1959

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H19BrN2
Molecular Weight	319.239
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=CC=CC=N2

InChI

InChIKey=ZDIGNSYAACHWNL-HNNXBMFYSA-N

InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a3b34f38-87da-4a38-ac73-66d28cc8647e&type=display | https://pubchem.ncbi.nlm.nih.gov/compound/Dexbrompheniramine

DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: https://www.drugbank.ca/drugs/DB00405 \| https://www.ncbi.nlm.nih.gov/pubmed/6634989	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Common cold 58 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b34f38-87da-4a38-ac73-66d28cc8647e	Palliative		Approved 8429	PANATUSS PEDIATRIC DROPS DXP Approved Use Uses: - Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold; - Temporarily relieves nasal congestions due to common cold; - For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date 1.12553283E12
Allergic rhinitis 100 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b34f38-87da-4a38-ac73-66d28cc8647e	Palliative		Approved 8429	PANATUSS PEDIATRIC DROPS DXP Approved Use Uses: - Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold; - Temporarily relieves nasal congestions due to common cold; - For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date 1.12553283E12

C_max

Value	Dose	Co-administered	Analyte	Population
27.98 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/	6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXBROMPHENIRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
234.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/	6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXBROMPHENIRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/	6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXBROMPHENIRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
0.3 % 1 times / day steady, ophthalmic Recommended Dose: 0.3 %, 1 times / day Route: ophthalmic Route: steady Dose: 0.3 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1687324/	unhealthy, adult n = 1 Health Status: unhealthy Condition: Allergic conjunctivitis Age Group: adult Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1687324/	Sources: https://pubmed.ncbi.nlm.nih.gov/1687324/
6 mg 4 times / day steady, oral Recommended Dose: 6 mg, 4 times / day Route: oral Route: steady Dose: 6 mg, 4 times / day Co-administed with:: pseudoephedrine sulfate(120 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/3981411/	healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3981411/	Sources: https://pubmed.ncbi.nlm.nih.gov/3981411/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:59269	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59269
ChemicalBook	CB6164683	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6164683
ZINC	ZINC000000000096	http://zinc15.docking.org/substances/ZINC000000000096

PubMed

Title	Date	PubMed
Non-antibiotic treatments for upper-respiratory tract infections (common cold).	2005 Dec	16291073

Patents

Sample Use Guides

In Vivo Use Guide

Children 6 years of age to under 12 years; 2 mL every 4 - 6 hours.

Route of Administration: Oral

Name

Type

Language

DEXBROMPHENIRAMINE

Official Name

English

BROMPHENIRAMINE D-FORM

Common Name

English

BROMPHENIRAMINE D-FORM [MI]

Common Name

English

dexbrompheniramine [INN]

Common Name

English

BROMPHENIRAMINE, (+)-

Common Name

English

DEXBROMPHENIRAMINE [VANDF]

Common Name

English

Dexbrompheniramine [WHO-DD]

Common Name

English

BROMPHENIRAMINE, (S)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578